Oncology

News

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

News

GSK confirms plan to buy cancer firm IDRx for $1bn

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

News

Galapagos' chief executive Paul Stoffels

Galapagos unveils plan to split, hiving off its drugs unit

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.

News

combination of directions for booted feet, two arrows

J&J says Rybrevant combo has survival edge over Tagrisso

Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.

News

GSK bags breakthrough status for bone cancer drug

GSK has claimed its second breakthrough designation from the FDA for B7-H3-targeted ADC, this time in osteosarcoma.

R&D

12 Questions with Peter Wickersham

Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology.

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

GSK confirms plan to buy cancer firm IDRx for $1bn

Galapagos unveils plan to split, hiving off its drugs unit

J&J says Rybrevant combo has survival edge over Tagrisso

GSK bags breakthrough status for bone cancer drug

12 Questions with Peter Wickersham

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Oncology

Editor's Picks